244 related articles for article (PubMed ID: 26392335)
1. Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.
Martin EW; Buzza MS; Driesbaugh KH; Liu S; Fortenberry YM; Leppla SH; Antalis TM
Oncotarget; 2015 Oct; 6(32):33534-53. PubMed ID: 26392335
[TBL] [Abstract][Full Text] [Related]
2. Proteolytic activation of the protease-activated receptor (PAR)-2 by the glycosylphosphatidylinositol-anchored serine protease testisin.
Driesbaugh KH; Buzza MS; Martin EW; Conway GD; Kao JP; Antalis TM
J Biol Chem; 2015 Feb; 290(6):3529-41. PubMed ID: 25519908
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of a urokinase activation-dependent anthrax toxin.
Rønø B; Rømer J; Liu S; Bugge TH; Leppla SH; Kristjansen PE
Mol Cancer Ther; 2006 Jan; 5(1):89-96. PubMed ID: 16432166
[TBL] [Abstract][Full Text] [Related]
4. Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Liu S; Aaronson H; Mitola DJ; Leppla SH; Bugge TH
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):657-62. PubMed ID: 12525700
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.
Liu S; Bugge TH; Frankel AE; Leppla SH
Methods Mol Biol; 2009; 539():175-90. PubMed ID: 19377974
[TBL] [Abstract][Full Text] [Related]
6. Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases.
Duru N; Pawar NR; Martin EW; Buzza MS; Conway GD; Lapidus RG; Liu S; Reader J; Rao GG; Roque DM; Leppla SH; Antalis TM
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2201423119. PubMed ID: 35867758
[TBL] [Abstract][Full Text] [Related]
7. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Liu S; Bugge TH; Leppla SH
J Biol Chem; 2001 May; 276(21):17976-84. PubMed ID: 11278833
[TBL] [Abstract][Full Text] [Related]
8. Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Peters DE; Hoover B; Cloud LG; Liu S; Molinolo AA; Leppla SH; Bugge TH
Toxicol Appl Pharmacol; 2014 Sep; 279(2):220-9. PubMed ID: 24971906
[TBL] [Abstract][Full Text] [Related]
9. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
Abi-Habib RJ; Singh R; Liu S; Bugge TH; Leppla SH; Frankel AE
Mol Cancer Ther; 2006 Oct; 5(10):2556-62. PubMed ID: 17041100
[TBL] [Abstract][Full Text] [Related]
10. Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.
Liu S; Redeye V; Kuremsky JG; Kuhnen M; Molinolo A; Bugge TH; Leppla SH
Nat Biotechnol; 2005 Jun; 23(6):725-30. PubMed ID: 15895075
[TBL] [Abstract][Full Text] [Related]
11. Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Fischer ES; Campbell WA; Liu S; Ghirlando R; Fattah RJ; Bugge TH; Leppla SH
Protein Sci; 2019 Jun; 28(6):1059-1070. PubMed ID: 30942916
[TBL] [Abstract][Full Text] [Related]
12. Testisin, a glycosyl-phosphatidylinositol-linked serine protease, promotes malignant transformation in vitro and in vivo.
Tang T; Kmet M; Corral L; Vartanian S; Tobler A; Papkoff J
Cancer Res; 2005 Feb; 65(3):868-78. PubMed ID: 15705885
[TBL] [Abstract][Full Text] [Related]
13. Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin.
Rozanov DV; Golubkov VS; Strongin AY
Int J Biochem Cell Biol; 2005 Jan; 37(1):142-54. PubMed ID: 15381157
[TBL] [Abstract][Full Text] [Related]
14. A+-helix of protein C inhibitor (PCI) is a cell-penetrating peptide that mediates cell membrane permeation of PCI.
Yang H; Wahlmüller FC; Sarg B; Furtmüller M; Geiger M
J Biol Chem; 2015 Jan; 290(5):3081-91. PubMed ID: 25488662
[TBL] [Abstract][Full Text] [Related]
15. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin.
Klimpel KR; Molloy SS; Thomas G; Leppla SH
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10277-81. PubMed ID: 1438214
[TBL] [Abstract][Full Text] [Related]
16. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
Su Y; Ortiz J; Liu S; Bugge TH; Singh R; Leppla SH; Frankel AE
Cancer Res; 2007 Apr; 67(7):3329-36. PubMed ID: 17409442
[TBL] [Abstract][Full Text] [Related]
17. A role for PACE4 in the proteolytic activation of anthrax toxin protective antigen.
Gordon VM; Rehemtulla A; Leppla SH
Infect Immun; 1997 Aug; 65(8):3370-5. PubMed ID: 9234799
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin.
Liu S; Netzel-Arnett S; Birkedal-Hansen H; Leppla SH
Cancer Res; 2000 Nov; 60(21):6061-7. PubMed ID: 11085528
[TBL] [Abstract][Full Text] [Related]
19. PRSS21/testisin inhibits ovarian tumor metastasis and antagonizes proangiogenic angiopoietins ANG2 and ANGPTL4.
Conway GD; Buzza MS; Martin EW; Duru N; Johnson TA; Peroutka RJ; Pawar NR; Antalis TM
J Mol Med (Berl); 2019 May; 97(5):691-709. PubMed ID: 30911775
[TBL] [Abstract][Full Text] [Related]
20. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer.
Netzel-Arnett S; Hooper JD; Szabo R; Madison EL; Quigley JP; Bugge TH; Antalis TM
Cancer Metastasis Rev; 2003; 22(2-3):237-58. PubMed ID: 12784999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
